{"nctId":"NCT00102960","briefTitle":"Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth","startDateStruct":{"date":"2005-07"},"conditions":["HIV Infections"],"count":377,"armGroups":[{"label":"Deferred therapy Arm","type":"EXPERIMENTAL","interventionNames":["Drug: Abacavir sulfate","Drug: Didanosine","Drug: Efavirenz","Drug: Lamivudine","Drug: Lopinavir/Ritonavir","Drug: Nevirapine","Drug: Zidovudine"]},{"label":"Early therapy for 40 weeks","type":"EXPERIMENTAL","interventionNames":["Drug: Abacavir sulfate","Drug: Didanosine","Drug: Efavirenz","Drug: Lamivudine","Drug: Lopinavir/Ritonavir","Drug: Nevirapine","Drug: Zidovudine"]},{"label":"Early therapy for 96 weeks","type":"EXPERIMENTAL","interventionNames":["Drug: Abacavir sulfate","Drug: Didanosine","Drug: Efavirenz","Drug: Lamivudine","Drug: Lopinavir/Ritonavir","Drug: Nevirapine","Drug: Zidovudine"]}],"interventions":[{"name":"Abacavir sulfate","otherNames":["ABC","Ziagen"]},{"name":"Didanosine","otherNames":["ddI","Videx"]},{"name":"Efavirenz","otherNames":["EFV","Stocrin"]},{"name":"Lamivudine","otherNames":["3TC","Epivir"]},{"name":"Lopinavir/Ritonavir","otherNames":["LPV/r","Kaletra"]},{"name":"Nevirapine","otherNames":["NVP","Viramune"]},{"name":"Zidovudine","otherNames":["AZT","Retrovir"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria for Infants:\n\nNOTE: Per Letter of Amendment dated 04/04/07, Part B of this study is no longer recruiting participants. Per Letter of Amendment dated 09/16/08 Arm 1 of this study is longer recruiting.\n\n* HIV infected\n* Antiretroviral naive. Infants who have previously received antiretroviral drugs used to prevent mother-to-child transmission are eligible for the study.\n* Parent or legal guardian willing to provide informed consent and comply with study requirements\n\nExclusion Criteria for Infants:\n\n* Any major life-threatening congenital abnormalities\n* Severe CDC Stage B or C disease\n* Liver enzyme, absolute neutrophil count, hemoglobin, electrolyte, creatinine, or clinical toxicity of Grade 3 or higher at screening\n* Any acute or clinically significant medical event that would preclude participation in the study. Randomization can take place as soon as the incurrent illness has resolved if the child is still less than or equal to 12 weeks of age.\n* Use of investigational drugs\n* Require certain medications. More information on this criterion can be found in the protocol.\n* Inability to tolerate oral medication\n* Birth weight less than 2 kg (4.4 lbs)","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Weeks","maximumAge":"12 Weeks","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time to Failure of First Line Therapy or Death","description":"To compare time to failure of first line ART (due to clinical, virological or immunological disease progression, or regimen-limiting ART toxicities) or death among three randomized arms (infants who receive early ART in Arms 2 and 3 and infants in whom ART is deferred until clinical or immunological disease progression in Arm 1) during the study (up to 4.8 years). The number of participants experiencing the events did not reach the 50% survival and thus median time-to-event is not be presented. Therefore we report the number of participants experiencing the events per Arm.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"32","spread":null},{"groupId":"OG002","value":"26","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Who Experienced Immunological Failure Defined as Failure of CD4% to Reach 20% or CD4% Falls Below 20% on Two Occasions, Within 4 Weeks, at Any Time After the First 24 Weeks of Therapy (Initial Therapy or Restart)","description":"This was part of the primary outcome measure above. The primary outcome was a composite endpoint. The primary outcome analysis only considered the initially enrolled children that were 377 in total (ART-Deferred n=125, Early therapy 40 weeks n=126 and Early therapy 96 weeks n=126). This was part of the primary outcome measure that was a composite endpoint.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"14","spread":null},{"groupId":"OG002","value":"11","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Who Experienced Regimen-limiting ART Drug Toxicity","description":"Development of toxicity requiring more than one drug substitution within the same class or a switch to a new class of drugs (regimen-limiting toxicity failure) or requiring a permanent treatment discontinuation. This was part of the primary outcome measure that was a composite endpoint.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Who Experienced Clinical Failure (Defined as Development of Severe CDC Stage B or Stage C Disease.) on Therapy.","description":"This included development of severe CDC Stage B or Stage C disease.This was part of the primary outcome measure that was a composite endpoint","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Who Experienced Virological Failure Defined as Confirmed HIV-1 RNA Value of at Least 10,000 Copies Per/ml Recorded on Two Consecutive Separate Occasions After 24 Weeks of Treatment (Initial Therapy or Restart)","description":"This was part of the primary outcome measure that was a composite endpoint that included confirmed HIV-1 RNA value of at least 10,000 copies per/ml recorded on two consecutive separate occasions after 24 weeks of treatment (initial therapy or restart).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Children Experiencing Severe CDC Stage B or Stage C Disease or Death (Cumulative After 3.5 Years)","description":"The outcome measure is defined as a number because it represents the number of children that experienced severe CDC Stage B or Stage C disease or death as defined in the outcome measure title above","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"28","spread":null},{"groupId":"OG002","value":"21","spread":null}]}]}]},{"type":"SECONDARY","title":"Total Occurrence of Grade 3 or 4 Clinical Events","description":"This was a secondary outcome measure that assessed the total count of Grade 3 or 4 (clinical or laboratory) adverse events.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"170","spread":null},{"groupId":"OG001","value":"118","spread":null},{"groupId":"OG002","value":"88","spread":null}]}]}]},{"type":"SECONDARY","title":"Total Occurrence of Grade 3 or 4 Laboratory Events","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"44","spread":null},{"groupId":"OG002","value":"33","spread":null}]}]}]},{"type":"SECONDARY","title":"Time From Randomization to Starting or Needing to Start Continuous Therapy","description":"Time from randomization to starting (deferred therapy Arm) or needing to start continuous therapy (early therapy 40 or 96 weeks)","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"33","spread":null},{"groupId":"OG002","value":"70","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Indicated Viral Resistance Mutations at the Time of Failure of First Line Therapy","description":"Resistance testing was performed on samples with a VLâ‰¥1000 c/ml together with the matched baseline sample, if available. Reverse transcriptase (NRTI and NNRTI) and protease (PI) inhibitor mutations were analysed using a validated in-house population-based sequencing assay and the IAS 2011 mutation list.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Death Alone or Death Plus Life Threatening Stage C Events or HIV Events Associated With Permanent End-organ Damage.","description":"This was a composite endpoint in which the number of children experiencing the events is reported. The number of participants experiencing the events did not reach the 50% survival and thus median time-to-event is not be presented. Therefore, we report the number of participants experiencing the events per Arm.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"13","spread":null}]}]}]},{"type":"SECONDARY","title":"Hospitalization Rates","description":"Hospitalisation rates in the three arms enrolled in the CHER study","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.6","spread":null},{"groupId":"OG001","value":"16.4","spread":null},{"groupId":"OG002","value":"14.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Hospitalisation","description":"This is the total number of days spent in hospital by the participants and is reported per arm","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1018","spread":null},{"groupId":"OG001","value":"533","spread":null},{"groupId":"OG002","value":"414","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to First Hospitalization","description":"To compare time to first hospitalization in the three randomized arms (infants who received early ART in Arms 2 and 3 and those who received deferred ART in Arm 1). Not all participants were hospitalized and thus the upper limits could not be evaluated.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.1","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"NA","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":79,"n":125},"commonTop":["Dermatitis","Gastroenteritis","Otitis Media","Pharyngitis","Bronchiolitis"]}}}